<
https://www.theguardian.com/society/article/2024/may/31/trial-results-for-new-lung-cancer-drug-are-off-the-charts-say-doctors>
"Doctors are hailing “off the chart” trial results that show a new drug stopped
lung cancer advancing for longer than any other treatment in medical history.
Lung cancer is the world’s leading cause of cancer death, accounting for about
1.8m deaths every year. Survival rates in those with advanced forms of the
disease, where tumours have spread, are particularly poor.
More than half of patients (60%) diagnosed with advanced forms of lung cancer
who took lorlatinib were still alive five years later with no progression in
their disease, data presented at the world’s largest cancer conference showed.
The rate was 8% in patients treated with a standard drug, the trial found.
The results are the longest progression-free survival (PFS) outcomes ever
recorded in patients with non-small cell lung cancer, the world’s most common
form of the disease. They were presented at the annual meeting of the American
Society of Clinical Oncology (Asco) in Chicago on Friday.
“To our knowledge these results are unprecedented,” said the study’s lead
author, Dr Benjamin Solomon, a medical oncologist at the Peter MacCallum Cancer
Centre in Melbourne, Australia."
Via
Fix the News:
<
https://fixthenews.com/good-news-water-sanitation-hygiene-poverty-cambodia-barn-owls-uk/>
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
